Developer docs
API playgroundTry for free, no card

Search company profiles

Aleva Neurotherapeutics

Full company profile

uuid0002bor

Namestring
Aleva Neurotherapeutics
Legal namestring
Aleva Neurotherapeutics SA
Websiteurl
aleva-neuro.com
Company typeenum
Private
Founded yearint
2008
Descriptiontext

Aleva Neurotherapeutics SA is a Swiss privately-held medical device company founded in 2008 as a spin-off of the EPFL Microsystems Laboratory of Prof. Philippe Renaud, headquartered at EPFL Innovation Park in Lausanne. The company designs, manufactures, and commercializes the directSTIM Directional Deep Brain Stimulation (DBS) system for the treatment of Parkinson's disease and Essential Tremor. Its core technical platform combines a MEMS-based 12-electrode directional lead (3-3-3-3 configuration with rounded contacts that avoid hotspots) and a 24-channel Multiple Independent Current Control (MICC) Implantable Pulse Generator — the highest number of independent directional contacts and current sources on the DBS market. The lead uses significantly less metal than competitors to reduce imaging artefacts in MRI/CT, and the system is CE-marked with full-body 1.5T MRI conditional labeling.

The company's business model is hardware sales of implantable directSTIM components (24-Channel IPG Model 12000, 12-Electrode Lead Model 11500, 12-Connector Extension Model 12100) plus clinician and patient accessories (Clinician Programmer Model 12200, Patient Programmer Charger Model 12300, External Trial Stimulator Model 12400, Magnet Model 12700), bundled with limited warranty and post-implant support services. Pricing is quote-based and not publicly disclosed. Aleva sells direct to leading neurological hospitals and clinics in Europe through an enterprise field-sales motion, supplemented by event-driven engagement at neuromodulation congresses, gated professional training, and multilingual patient content (English, German, Turkish). US market entry is being built through an FDA-approved Investigational Device Exemption (IDE) study at up to 15 institutions enrolling up to 136 patients to support a future PMA application.

Aleva has raised approximately $74.3M in disclosed funding across multiple rounds from 2008 to 2021, with investors including BB Biotech Ventures, BioMedPartners, Forrestal Capital, Initiative Capital Romandie, Kinled Holding, Greatbatch, and KREAXI. The company holds 13 patent families and 90 granted patents in DBS technologies for neurological and psychiatric diseases. Leadership includes co-founder and CSO André Mercanzini, co-founder and managing partner Claudio Pollo (lead author on the landmark 2014 Brain paper on directional DBS), Chairman Jeffrey B. Jump, CFO Alexandre Grassin, and CEO Alain Jordan (as of September 2022, succeeding Stefano Alfonsi). Operations are GDPR-compliant and software development is conducted under an ISO 13485 quality management system.

Short descriptiontext

Aleva Neurotherapeutics is a Lausanne-based medical device company that designs, manufactures, and commercializes the directSTIM directional Deep Brain Stimulation system for Parkinson's disease and Essential Tremor, selling direct to leading neurological hospitals and clinics in Europe while pursuing US FDA approval via an IDE-enabling PMA trial.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersLausanne, Switzerland
HQ citystring
Lausanne
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
directional deep brain stimulation, implantable pulse generator, neurostimulation medical devices, Parkinson disease therapy, essential tremor treatment
Industry2 codes
PRIMARYHLAHAEAK
Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLALAGAC
Neurology Telemedicine Platforms
Healthcare & Life Sciences/Telehealth Platforms/Specialty Telemedicine Platforms (e.g., dermatology, cardiology, neurology)
NAICS code2 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Computer Systems Design Services541512
SIC code2 codes
  • Electromedical & Electrotherapeutic Apparatus3845
  • Surgical & Medical Instruments & Apparatus3841
Product category
Neurostimulation Medical Devices
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model2 records
1directSTIM DBS System Hardware Sales
TypeHardware Sales
Description

Sale of implantable directSTIM DBS system components (24-Channel IPG Model 12000, 12-Electrode Lead Model 11500, 12-Connector Extension Model 12100) plus accessories (Clinician Programmer, Patient Programmer Charger, Magnet) to neurological clinics and hospitals performing DBS surgery.

aleva-neuro.com
2Limited Warranty and After-Sales Support Services
TypeManaged Services
Description

Limited warranty coverage and customer/technical support services tied to the implanted directSTIM DBS system, including replacement documentation, customer service line, and post-implant follow-up resources.

aleva-neuro.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1directSTIM™
Description

Aleva's flagship Directional Deep Brain Stimulation (DBS) System featuring a 12-electrode lead and 24-channel rechargeable Implantable Pulse Generator, CE-marked for treating Parkinson's disease and essential tremor in Europe.

aleva-neuro.com
Core offering1 text field

Aleva Neurotherapeutics develops and commercializes the directSTIM™ Deep Brain Stimulation (DBS) System, an implantable neurostimulation platform comprising a 24-channel rechargeable Implantable Pulse Generator (Model 12000), a 12-electrode directional lead (Model 11500), a 12-connector extension (Model 12100), an External Pulse Generator (Model 12400), a Clinician Programmer (Model 12200), a Patient Programmer Charger (Model 12300), and a Magnet (Model 12700). The system is intended for the treatment of Parkinson's disease and Essential Tremor, and uses Multiple Independent Current Control to enable directional current steering for patient-specific therapy.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 24 fully independent directional contacts (highest on the market) combined with 24 independent current sources in the IPG
+5 more records
Product overview1 text field

Aleva Neurotherapeutics offers a single integrated medical-device platform — the directSTIM™ DBS System — rather than a multi-product portfolio. The platform is built around a core implanted subsystem (the directSTIM™ 24-Channel Implantable Pulse Generator Model 12000, the directSTIM™ 12-Electrode Lead Model 11500 and the directSTIM™ 12-Connector Extension Model 12100) that together deliver directional deep brain stimulation for Parkinson's disease and essential tremor. It is complemented by an external accessory subsystem (the directSTIM™ External Pulse Generator Model 12400 trial stimulator, the directSTIM™ Clinician Programmer Model 12200, the directSTIM™ Patient Programmer Charger Model 12300, and the directSTIM™ Magnet Model 12700) that supports intraoperative testing, programming and patient control. Aleva's roadmap layers a planned digital, AI-powered clinical-data ecosystem on top of the hardware to power surgical and programming insights.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
1Swiss Federal Institute of Technology (EPFL) Microsystems Laboratory of Prof. Philippe Renaud
Strategic tierFlagship / Origin PartnerTypeStrategic or Co-development Partner
Description

EPFL Microsystems Laboratory is the originating research partner that developed the MEMS technology underlying the directSTIM 12-electrode lead. Aleva Neurotherapeutics was founded as a spin-off of EPFL specifically to commercialize this technology for DBS applications. The lead technology is publicly attributed to EPFL's lmis4 laboratory.

aleva-neuro.com
2German Society for Neuromodulation (Deutsche Gesellschaft für Neuromodulation e.V.)
Strategic tierCore Event PartnerTypeGTM or Marketing Partner
Description

Aleva participated as an exhiber/attendee at the 17th Annual Conference of the German Society for Neuromodulation (November 4-5, 2022, Victor's Residenz-Hotel Gera, Berliner Strasse 38, 07545 Gera, Germany). Used to reach European movement disorder specialists.

aleva-neuro.com
3U.S. Food and Drug Administration (FDA)
Strategic tierCritical Path-To-Market Partner For Us CommercializationTypeOthers
Description

Aleva received FDA approval for an Investigational Device Exemption (IDE) study in February 2022 to begin a US PMA trial at up to 15 US institutions with up to 136 US patients. The IDE protocol collects safety and efficacy data to support a future PMA application.

aleva-neuro.com
4Up to 15 US clinical study sites (under FDA IDE)
Strategic tierCore Us Launch PartnersTypeImplementation/ SI/ Consulting Partner
Description

Aleva is committed to starting the PMA trial in parallel with the ongoing post-market clinical follow-up study in select European neurological clinics. The US trial will enroll up to 136 US patients across up to 15 US institutions, generating safety and efficacy data for the PMA application.

aleva-neuro.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Global leader in DBS with the Activa system and the largest installed base of implantable neurostimulators worldwide. Directly competes with Aleva in the same indication (Parkinson's, essential tremor, dystonia) and is Aleva's most important incumbent competitor.

TypeDirect peer
Description

Markets the Vercise DBS System with directional leads and Multiple Independent Current Control technology, directly competing with Aleva's directSTIM in Parkinson's and essential tremor. Boston Scientific's Vercise platform uses similar directional-stimulation concepts and overlaps on the same clinical customer base.

3Abbott
TypeDirect peer
Description

Markets the Infinity DBS System (acquired via St. Jude Medical), one of the three major incumbent DBS systems. Directly competes with Aleva in the same implant category, customer base, and indications, with established US and global commercial reach.

4SceneRay
TypeDirect peer
Description

Chinese neuromodulation company developing DBS systems for movement disorders. Competes with Aleva in the same DBS category, primarily in the Chinese market, and represents a regional alternative with similar directional-stimulation concepts.

5Beijing Pins Medical
TypeDirect peer
Description

Chinese medical device company offering the PINS (Pins Medical) DBS system for Parkinson's disease and other movement disorders. Directly comparable DBS product and indications to Aleva, but primarily serves the China market.

TypeEmerging player
Description

Markets the RNS System, a closed-loop responsive neurostimulator for epilepsy rather than DBS, but operates in the same implantable neurostimulation category, with comparable hospital/neurology sales channels and a similar company-size profile.

TypeBroad incumbent
Description

Incumbent neuromodulation company offering Vagus Nerve Stimulation (VNS) therapy for epilepsy and depression. Operates in the broader implantable neuromodulation space, sharing sales channels with hospital neurology and neurosurgery customers, though not in the DBS subsegment.

TypeBroad incumbent
Description

Markets the HF10 high-frequency spinal cord stimulation system, operating in the broader implantable neurostimulation category. Comparable in that it sells implantable stimulation devices to neurosurgery/pain-medicine specialists, but addresses a different indication.

TypeEmerging player
Description

Early-stage DBS company developing DBS for Alzheimer's disease, using Medtronic Activa hardware in clinical studies. Operates in the same DBS clinical/research category and would compete for indication-expansion mind-share if it advances.

10MicroPort Scientific
TypeRegional player
Description

China-based medical device conglomerate with a neuromodulation portfolio that has historically included DBS-adjacent technologies. Comparable in category and in serving emerging DBS markets, particularly in Asia, with broad device-portfolio commercial reach.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles14 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds9 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors11 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Aleva Neurotherapeutics

Neurostimulation Medical Devicesaleva-neuro.com

Aleva Neurotherapeutics is a Lausanne-based medical device company that designs, manufactures, and commercializes the directSTIM directional Deep Brain Stimulation system for Parkinson's disease and Essential Tremor, selling direct to leading neurological hospitals and clinics in Europe while pursuing US FDA approval via an IDE-enabling PMA trial.

What Aleva Neurotherapeutics does

Aleva Neurotherapeutics SA is a Swiss privately-held medical device company founded in 2008 as a spin-off of the EPFL Microsystems Laboratory of Prof. Philippe Renaud, headquartered at EPFL Innovation Park in Lausanne. The company designs, manufactures, and commercializes the directSTIM Directional Deep Brain Stimulation (DBS) system for the treatment of Parkinson's disease and Essential Tremor. Its core technical platform combines a MEMS-based 12-electrode directional lead (3-3-3-3 configuration with rounded contacts that avoid hotspots) and a 24-channel Multiple Independent Current Control (MICC) Implantable Pulse Generator — the highest number of independent directional contacts and current sources on the DBS market. The lead uses significantly less metal than competitors to reduce imaging artefacts in MRI/CT, and the system is CE-marked with full-body 1.5T MRI conditional labeling.

The company's business model is hardware sales of implantable directSTIM components (24-Channel IPG Model 12000, 12-Electrode Lead Model 11500, 12-Connector Extension Model 12100) plus clinician and patient accessories (Clinician Programmer Model 12200, Patient Programmer Charger Model 12300, External Trial Stimulator Model 12400, Magnet Model 12700), bundled with limited warranty and post-implant support services. Pricing is quote-based and not publicly disclosed. Aleva sells direct to leading neurological hospitals and clinics in Europe through an enterprise field-sales motion, supplemented by event-driven engagement at neuromodulation congresses, gated professional training, and multilingual patient content (English, German, Turkish). US market entry is being built through an FDA-approved Investigational Device Exemption (IDE) study at up to 15 institutions enrolling up to 136 patients to support a future PMA application.

Aleva has raised approximately $74.3M in disclosed funding across multiple rounds from 2008 to 2021, with investors including BB Biotech Ventures, BioMedPartners, Forrestal Capital, Initiative Capital Romandie, Kinled Holding, Greatbatch, and KREAXI. The company holds 13 patent families and 90 granted patents in DBS technologies for neurological and psychiatric diseases. Leadership includes co-founder and CSO André Mercanzini, co-founder and managing partner Claudio Pollo (lead author on the landmark 2014 Brain paper on directional DBS), Chairman Jeffrey B. Jump, CFO Alexandre Grassin, and CEO Alain Jordan (as of September 2022, succeeding Stefano Alfonsi). Operations are GDPR-compliant and software development is conducted under an ISO 13485 quality management system.

Aleva Neurotherapeutics firmographics

Firmographics
Name
Aleva Neurotherapeutics
Legal name
Aleva Neurotherapeutics SA
Website
https://aleva-neuro.com
Company type
Private
Founded year
2008
Operating status
Operating
Headcount range
1–10 employees
Short description
Aleva Neurotherapeutics is a Lausanne-based medical device company that designs, manufactures, and commercializes the directSTIM directional Deep Brain Stimulation system for Parkinson's disease and Essential Tremor, selling direct to leading neurological hospitals and clinics in Europe while pursuing US FDA approval via an IDE-enabling PMA trial.
Ownership category
akta.pro rank

Aleva Neurotherapeutics industry classification

Industry
Product category
Neurostimulation Medical Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Computer Systems Design Services (541512)
SIC
Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHAEAK
Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLALAGAC
Neurology Telemedicine Platforms
Healthcare & Life Sciences/Telehealth Platforms/Specialty Telemedicine Platforms (e.g., dermatology, cardiology, neurology)

Keywords

  • Directional deep brain stimulation
  • Implantable pulse generator
  • Neurostimulation medical devices
  • Parkinson disease therapy
  • Essential tremor treatment

Where Aleva Neurotherapeutics is headquartered

Location

Headquarters

HQ city
Lausanne
HQ country
Switzerland
HQ region
Europe

Offices2 records

Markets served

Aleva Neurotherapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales

Revenue model

  1. directSTIM DBS System Hardware Sales: Sale of implantable directSTIM DBS system components (24-Channel IPG Model 12000, 12-Electrode Lead Model 11500, 12-Connector Extension Model 12100) plus accessories (Clinician Programmer, Patient Programmer Charger, Magnet) to neurological clinics and hospitals performing DBS surgery.
  2. Limited Warranty and After-Sales Support Services: Limited warranty coverage and customer/technical support services tied to the implanted directSTIM DBS system, including replacement documentation, customer service line, and post-implant follow-up resources.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels7 records

Aleva Neurotherapeutics product offering

Product offering

Core offering

Aleva Neurotherapeutics develops and commercializes the directSTIM™ Deep Brain Stimulation (DBS) System, an implantable neurostimulation platform comprising a 24-channel rechargeable Implantable Pulse Generator (Model 12000), a 12-electrode directional lead (Model 11500), a 12-connector extension (Model 12100), an External Pulse Generator (Model 12400), a Clinician Programmer (Model 12200), a Patient Programmer Charger (Model 12300), and a Magnet (Model 12700). The system is intended for the treatment of Parkinson's disease and Essential Tremor, and uses Multiple Independent Current Control to enable directional current steering for patient-specific therapy.

Product overview

Aleva Neurotherapeutics offers a single integrated medical-device platform — the directSTIM™ DBS System — rather than a multi-product portfolio. The platform is built around a core implanted subsystem (the directSTIM™ 24-Channel Implantable Pulse Generator Model 12000, the directSTIM™ 12-Electrode Lead Model 11500 and the directSTIM™ 12-Connector Extension Model 12100) that together deliver directional deep brain stimulation for Parkinson's disease and essential tremor. It is complemented by an external accessory subsystem (the directSTIM™ External Pulse Generator Model 12400 trial stimulator, the directSTIM™ Clinician Programmer Model 12200, the directSTIM™ Patient Programmer Charger Model 12300, and the directSTIM™ Magnet Model 12700) that supports intraoperative testing, programming and patient control. Aleva's roadmap layers a planned digital, AI-powered clinical-data ecosystem on top of the hardware to power surgical and programming insights.

Differentiator

Problem solved

Functional benefit

Brands

  • directSTIM™: Aleva's flagship Directional Deep Brain Stimulation (DBS) System featuring a 12-electrode lead and 24-channel rechargeable Implantable Pulse Generator, CE-marked for treating Parkinson's disease and essential tremor in Europe.

Quantifiable outcome

  • 24 fully independent directional contacts (highest on the market) combined with 24 independent current sources in the IPG
  • +5 more outcomes

Companies that use Aleva Neurotherapeutics

Customer profile

Segments3 records

Ideal customer profiles1 record

Aleva Neurotherapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature6 records

Aleva Neurotherapeutics partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered flagship / origin partner, core event partner, critical path-to-market partner for us commercialization and core us launch partners.

  • Swiss Federal Institute of Technology (EPFL) Microsystems Laboratory of Prof. Philippe Renaudflagship / origin partnerStrategic or Co-development PartnerEPFL Microsystems Laboratory is the originating research partner that developed the MEMS technology underlying the directSTIM 12-electrode lead. Aleva Neurotherapeutics was founded as a spin-off of EPFL specifically to commercialize this technology for DBS applications. The lead technology is publicly attributed to EPFL's lmis4 laboratory.
  • German Society for Neuromodulation (Deutsche Gesellschaft für Neuromodulation e.V.)core event partnerGTM or Marketing PartnerAleva participated as an exhiber/attendee at the 17th Annual Conference of the German Society for Neuromodulation (November 4-5, 2022, Victor's Residenz-Hotel Gera, Berliner Strasse 38, 07545 Gera, Germany). Used to reach European movement disorder specialists.
  • U.S. Food and Drug Administration (FDA)critical path-to-market partner for us commercializationOthersAleva received FDA approval for an Investigational Device Exemption (IDE) study in February 2022 to begin a US PMA trial at up to 15 US institutions with up to 136 US patients. The IDE protocol collects safety and efficacy data to support a future PMA application.
  • Up to 15 US clinical study sites (under FDA IDE)core us launch partnersImplementation/ SI/ Consulting PartnerAleva is committed to starting the PMA trial in parallel with the ongoing post-market clinical follow-up study in select European neurological clinics. The US trial will enroll up to 136 US patients across up to 15 US institutions, generating safety and efficacy data for the PMA application.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Aleva Neurotherapeutics competitors and assessment

Company assessment

Direct peers

  • Medtronic: Global leader in DBS with the Activa system and the largest installed base of implantable neurostimulators worldwide. Directly competes with Aleva in the same indication (Parkinson's, essential tremor, dystonia) and is Aleva's most important incumbent competitor.
  • Boston Scientific: Markets the Vercise DBS System with directional leads and Multiple Independent Current Control technology, directly competing with Aleva's directSTIM in Parkinson's and essential tremor. Boston Scientific's Vercise platform uses similar directional-stimulation concepts and overlaps on the same clinical customer base.
  • Abbott: Markets the Infinity DBS System (acquired via St. Jude Medical), one of the three major incumbent DBS systems. Directly competes with Aleva in the same implant category, customer base, and indications, with established US and global commercial reach.
  • SceneRay: Chinese neuromodulation company developing DBS systems for movement disorders. Competes with Aleva in the same DBS category, primarily in the Chinese market, and represents a regional alternative with similar directional-stimulation concepts.
  • Beijing Pins Medical: Chinese medical device company offering the PINS (Pins Medical) DBS system for Parkinson's disease and other movement disorders. Directly comparable DBS product and indications to Aleva, but primarily serves the China market.

Emerging players

  • NeuroPace: Markets the RNS System, a closed-loop responsive neurostimulator for epilepsy rather than DBS, but operates in the same implantable neurostimulation category, with comparable hospital/neurology sales channels and a similar company-size profile.
  • Functional Neuromodulation: Early-stage DBS company developing DBS for Alzheimer's disease, using Medtronic Activa hardware in clinical studies. Operates in the same DBS clinical/research category and would compete for indication-expansion mind-share if it advances.

Broad incumbents

  • LivaNova: Incumbent neuromodulation company offering Vagus Nerve Stimulation (VNS) therapy for epilepsy and depression. Operates in the broader implantable neuromodulation space, sharing sales channels with hospital neurology and neurosurgery customers, though not in the DBS subsegment.
  • Nevro: Markets the HF10 high-frequency spinal cord stimulation system, operating in the broader implantable neurostimulation category. Comparable in that it sells implantable stimulation devices to neurosurgery/pain-medicine specialists, but addresses a different indication.

Regional players

  • MicroPort Scientific: China-based medical device conglomerate with a neuromodulation portfolio that has historically included DBS-adjacent technologies. Comparable in category and in serving emerging DBS markets, particularly in Asia, with broad device-portfolio commercial reach.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Aleva Neurotherapeutics social profiles

Digital presence

Aleva Neurotherapeutics compliance and trust

Trust signal

Compliance2 records

Aleva Neurotherapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Aleva Neurotherapeutics leadership team

Management profile

Number of profiles

Profiles14 records

Aleva Neurotherapeutics funding detail

Funding detail

Funding overview

Funding rounds9 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Aleva Neurotherapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aleva Neurotherapeutics

What does Aleva Neurotherapeutics do?

Aleva Neurotherapeutics develops and commercializes the directSTIM™ Deep Brain Stimulation (DBS) System, an implantable neurostimulation platform comprising a 24-channel rechargeable Implantable Pulse Generator (Model 12000), a 12-electrode directional lead (Model 11500), a 12-connector extension (Model 12100), an External Pulse Generator (Model 12400), a Clinician Programmer (Model 12200), a Patient Programmer Charger (Model 12300), and a Magnet (Model 12700). The system is intended for the treatment of Parkinson's disease and Essential Tremor, and uses Multiple Independent Current Control to enable directional current steering for patient-specific therapy.

Is Aleva Neurotherapeutics a public or private company?

Aleva Neurotherapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Aleva Neurotherapeutics founded?

Aleva Neurotherapeutics was founded in 2008. It employs 1 to 10 people.

Where is Aleva Neurotherapeutics based?

Aleva Neurotherapeutics is headquartered in Lausanne, Switzerland, in the Europe region.

How does Aleva Neurotherapeutics make money?

Two revenue lines are on record. directSTIM DBS System Hardware Sales are the primary driver. The others are limited Warranty and After-Sales Support Services.

Who are Aleva Neurotherapeutics's main competitors?

Direct peers on record are Medtronic, Boston Scientific, Abbott, SceneRay and Beijing Pins Medical. Emerging players are NeuroPace and Functional Neuromodulation. Broad incumbents are LivaNova and Nevro. MicroPort Scientific is listed as a regional player.

Does Aleva Neurotherapeutics have an API?

No public API is recorded for Aleva Neurotherapeutics.

What industry is Aleva Neurotherapeutics in?

Aleva Neurotherapeutics's product category is Neurostimulation Medical Devices. Its primary akta.pro industry code is HLAHAEAK, Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS), with a secondary code of HLALAGAC, Neurology Telemedicine Platforms. Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PrtimesASEAN Deep Brain Stimulation Devices Market to Reach US$ 36.6 Million by 2033 – PR TimesAccording to market research by Business Market Insights, the ASEAN deep brain stimulation devices market is projected to grow from US$ 18.3 million in 2025 to US$ 36.6 million by 2033, representing a compound annual growth rate of 9.0%. The market is driven by increasing prevalence of neurological disorders, improving healthcare infrastructure, and growing medical tourism in countries such as Singapore, Malaysia, Thailand, and Indonesia.Mpo-magNerve Agents: A Look at the Neurostimulation Device MarketLungpacer Medical Inc., a Simon Fraser University spinout, received FDA premarket approval for its AeroPace System in December 2024 and CMS reimbursement approval, making it the first and only temporary transvenous diaphragm neurostimulation device for mechanically ventilated patients, with hospitals eligible for up to $23,650.90 in additional Medicare reimbursement per case. The article surveys the broader neurostimulation market, highlighting competitive developments from Medtronic, Abbott, Boston Scientific, NeuroPace, and Aleva Neurotherapeutics in deep brain stimulation and spinal cord stimulation, with Grand View Research projecting the global sector to grow from $6.37 billion in 2025 to $13.93 billion in 2033 at a 10.3% annual rate. Boston Scientific further reinforced its chronic pain portfolio by acquiring Nalu Medical for $533 million, purchasing the remaining equity in the miniaturized neurostimulation implant maker it had invested in since 2017.Zion Market ResearchDeep Brain Stimulation Devices Market Size, Share and ForecastA market research report projects the global Deep Brain Stimulation Devices market will grow from approximately USD 1.3 billion in 2023 to nearly USD 3.1 billion by 2032, driven by rising prevalence of neurological disorders and technological advancements. Key players identified in this competitive landscape include Boston Scientific Corporation, Medtronic, Inc., Aleva Neurotherapeutics SA, and St. Jude Medical, Inc.Aleva-NeuroAleva NeuroAleva Neurotherapeutics announced that its directSTIM™ Deep Brain Stimulation System has received MRI approval, a regulatory milestone for the company's directional DBS technology. The Swiss-based medical device firm aims to expand its market presence by partnering with leading neurological clinics in Europe and targeting global markets following this development.PR NewswireNerve repair and regeneration market 2023-2027: Growth opportunities led by Abbott Laboratories and ALEVA NEUROTHERAPEUTICS SA - TechnavioTechnavio published a market research report projecting the global nerve repair and regeneration market to grow by USD 4,891.9 million from 2022 to 2027, accelerating at a CAGR of 11.23%. The report identifies Abbott Laboratories and ALEVA NEUROTHERAPEUTICS SA as key vendors driving growth opportunities, with neuromodulation devices segment expected to hold the highest market share during the forecast period. Rising prevalence of neurological disorders such as Alzheimer's disease, an aging population, and increasing nerve injuries are cited as primary market growth drivers.startupticker.chAleva receives FDA approval to start US StudyAleva Neurotherapeutics received FDA approval for an Investigational Device Exemption (IDE) study for its directSTIM deep brain stimulation device. The approval follows safety and clinical data review, with the protocol designed to support a future PMA application. The company aims to bring the device to the U.S. market.BioWorldAleva launches postmarket study on its directional DBS system for neurology conditionsAleva Neurotherapeutics reported the first successful implantation of its directional deep brain stimulation system in a Parkinson's disease patient. The procedure was performed by neurosurgeon Stephan Sobottka at the University Hospital Carl Gustav Carus in Dresden, Germany.startupticker.chSuccessful collaboration between Aleva Neurotherapeutics and DIXI MedicalDIXI Medical is investing a second tranche into Adept Neuro, a joint venture with Aleva Neurotherapeutics, ahead of schedule. The company targets US and EU regulatory certifications, with the new SEEG electrode generation on the US market in H1 2022 and a follow-up product in H2 2023.GlobeNewswireAdept Neuro Reaches Key Milestone in the Development of Novel Intracerebral Stereoelectroencephalography (SEEG) ElectrodesAdept Neuro, a joint venture of DIXI Medical and Aleva Neurotherapeutics, announced a milestone in developing MEMS-enabled SEEG electrodes for epilepsy. DIXI Medical is investing its second tranche ahead of schedule, targeting US and EU regulatory certifications. The new product is expected on the US market in H1 2022, with an enhanced version by H2 2023.GlobeNewswireAleva Neurotherapeutics Recruits First Patient into its PMCF Study with its directSTIM™ Directional Deep Brain Stimulation SystemAleva Neurotherapeutics implanted its first patient with the directSTIM directional deep brain stimulation system at the University Hospital of Dresden. The post-market clinical follow-up study in Germany will include up to 60 patients, with final results expected in the first half of 2022. The company aims to obtain US FDA IDE approval in Q4 2021.